Table 1.
The relationship between TSR and major clinico-pathological characteristics.
| Characteristics | Total, n (%) | Stroma-high, n (%) | Stroma-low, n (%) | P value |
|---|---|---|---|---|
| Age (years) | 0.244 | |||
| ≤ 50 | 149 (62.1) | 87 (59.2) | 62 (66.7) | |
| > 50 | 91 (37.9) | 60 (40.8) | 31 (33.3) | |
| Menopausal status | 0.031 | |||
| Premenopausal | 134 (55.8) | 74 (50.3) | 60 (64.5) | |
| Postmenopausal | 106 (44.2) | 73 (49.7) | 33 (35.5) | |
| Histological type | ||||
| Invasive ductal carcinoma | 191 (79.6) | 115 (78.2) | 76 (81.7) | 0.514 |
| Others | 49 (20.4) | 32(21.8) | 17(18.3) | |
| T stage (cm) | 0.629 | |||
| T1 (T ≤ 2) | 35 (15.0) | 19 (12.9) | 16 (17.2) | |
| T2 (2 < T ≤ 5) | 162 (67.5) | 102 (69.4) | 60 (64.5) | |
| T3 (T > 5) | 43 (17.5) | 26 (17.7) | 17 (18.3) | |
| N status | 0.205 | |||
| N negative | 109 (45.4) | 62 (42.2) | 47 (50.5) | |
| N positive | 131 (54.6) | 85 (57.8) | 46 (49.5) | |
| Histological grade | 0.622 | |||
| I | 40 (16.7) | 25 (17.0) | 15 (16.1) | |
| II | 141 (58.8) | 83 (56.5) | 58 (62.4) | |
| III | 59 (24.6) | 39 (26.5) | 20 (21.5) | |
| ER statusa | 0.277 | |||
| Positive | 106 (44.2) | 69 (46.9) | 37 (39.8) | |
| Negative | 134 (55.8) | 78 (53.1) | 56 (60.2) | |
| PR statusa | 0.499 | |||
| Positive | 107 (44.6) | 63 (42.9) | 44 (47.3) | |
| Negative | 133 (55.4) | 84 (57.1) | 49 (52.7) | |
| HER2 geneb | ||||
| Amplification | 51 (21.3) | 26 (17.7) | 25 (26.9) | 0.090 |
| Non-amplification | 189 (78.7) | 121 (82.3) | 68 (73.1) |
aER, PR was determined by immunohistochemistry staining according to guideline 19; bHER2 gene was determined by fluorescent in-situ hybridization (FISH) according to guideline 20. BC: breast cancer; T: tumor; N: node; TSR: tumor-stromal ratio; ER: estrogen receptor; HER2: human epidermal growth factor receptor-2.